Elizabeth Lorenzi

Aug 21, 2024 | digitalcommons.library.tmc.edu | Thomas Hills |Elizabeth Lorenzi |Lindsay Berry |Murali Shyamsundar

BACKGROUND: The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no statin (control) in critically ill patients with Covid-19 who were not receiving statins at baseline.